

1 **A Systematic Review on the Effect of Diabetes Mellitus on the Pharmacokinetics of**  
2 **Tuberculosis Drugs**

3

4

5 **Authors:** Muge Cevik<sup>1\*</sup>, Ann Sturdy<sup>2</sup>, Alberto Enrico Maraolo<sup>3</sup>, Bart G.J. Dekkers<sup>4</sup>, Onno  
6 W. Akkerman<sup>5,6</sup>, Stephen H. Gillespie<sup>1</sup>, Jan Willem C. Alffenaar<sup>7-9</sup>

7

8

9 **Affiliations:**

10 1. Division of Infection and Global Health Research, School of Medicine, University of St  
11 Andrews, UK

12 2. Department of Infectious Disease, Faculty of Medicine, Imperial College London, UK

13 3. Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University  
14 of Naples 'Federico II', Italy

15 4. University of Groningen, University Medical Center Groningen, Department of Clinical  
16 Pharmacy and Pharmacology, Groningen, the Netherlands

17 5. University of Groningen, University Medical Center Groningen, Department of  
18 Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands

19 6. University of Groningen, University Medical Center Groningen, Tuberculosis Center  
20 Beatrixoord, Haren, the Netherlands

21 7. The University of Sydney Institute for Infectious Diseases, Sydney, NSW, Australia.

22 8. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,  
23 Sydney, NSW, Australia.

24 9. Westmead Hospital, Westmead, NSW, Australia

25

26 **Running head : Pharmacokinetics of TB Drugs in DM**

27

28 **\*Corresponding author:**

29 Dr Muge Cevik

30 Division of Infection and Global Health Research,

31 School of Medicine, University of St Andrews, Fife, KY16 9TF

32 Telephone number: +447732800814

33 Email address: mc349@st-andrews.ac.uk

34

35

36 **Abstract**

37

38 **Objectives**

39 The coexistence of TB and DM (TB-DM) has been associated with an increased risk of  
40 treatment failure, death, delayed culture conversion and drug resistance. As plasma  
41 concentrations may influence clinical outcomes, we evaluated the evidence on the PK of  
42 TB drugs in DM individuals to guide management.

43

44 **Methods**

45 We performed a systematic review and meta-analysis through searches of major  
46 databases from 1946 to 6 July 2023. PROSPERO (CRD42022323566).

47

48 **Results**

49 Out of 4173 potentially relevant articles, we identified 16 studies assessing rifampicin PK,  
50 9 on isoniazid, 8 on pyrazinamide and 3 on ethambutol. Two studies reported on second  
51 line anti-TB drugs. According to our analysis, RIF T<sub>max</sub> was significantly prolonged in  
52 patients with DM compared to non-DM patients. We found no significant differences for  
53 RIF C<sub>max</sub>, AUC<sub>0-24</sub> or C<sub>2hr</sub>, INH C<sub>2hr</sub>, PZA C<sub>2hr</sub>, PZA T<sub>max</sub> and ETB T<sub>max</sub>. While RIF C<sub>2hr</sub>  
54 was slightly reduced in TB-DM patients, this finding was not statistically significant.

55

56 **Conclusions**

57 This review comprehensively examines the impact of DM on the PK of TB drugs. We  
58 observed significant heterogeneity among studies. Given the association between lower  
59 plasma concentrations and poor clinical outcomes among DM patients, we recommend a  
60 higher dose limit to correct for larger bodyweight of patients with DM.

## 61 INTRODUCTION

62

63 The global tuberculosis (TB) burden remains substantial, with more than 10 million people  
64 newly diagnosed per year.<sup>1</sup> Non-communicable diseases continue to pose challenges for  
65 both the management of TB and control strategies. For instance, over the next 10 years,  
66 the prevalence of Diabetes mellitus (DM) is estimated to double globally, with TB and DM  
67 co-epidemic surpassing the TB-HIV coinfection in low-middle income countries.<sup>2,3</sup> More  
68 alarmingly DM is increasing in the same population that is at high risk for developing TB.

69

70 DM is specifically important for the TB epidemic and future policies as DM has been  
71 shown to double the risk of acquiring TB<sup>4,5</sup> and DM patients have three-fold increased risk  
72 of progression to active disease,<sup>5</sup> highlighting that increased prevalence of DM will help to  
73 maintain the TB epidemic. In addition, TB-DM patients experience increased risk of severe  
74 disease, treatment failure, relapse and increased risk of death<sup>6,7</sup> as well as delayed  
75 sputum culture conversion and a greater risk of developing drug resistance.<sup>8,9</sup>

76

77 There is however limited practical evidence to underpin treatment guidelines for TB-DM  
78 patients, such as length of treatment and drug dosing. This is important as plasma  
79 concentrations of TB medications may affect the clinical outcome. Zheng et al<sup>10</sup> showed  
80 an association between plasma concentrations of first line anti-TB drugs, culture  
81 conversion and clinical outcomes. Alfarisi et al.<sup>11</sup> demonstrated a positive association  
82 between time to culture conversion and isoniazid (INH) and rifampicin (RIF) concentrations  
83 and negative association with pyrazinamide (PZA) levels in DM patients. Pharmacokinetics  
84 (PK) of many other drugs are known to be altered in diabetic individuals.<sup>12</sup> DM may affect  
85 kidney function, gastric emptying and drug metabolism pathways.<sup>12</sup> This highlights the  
86 importance of understanding PK in TB-DM population.<sup>13</sup>

87

88 In this systematic review and meta-analysis, we evaluated the available evidence on the  
89 PK of antituberculosis drugs in diabetic individuals to provide in-depth analysis to guide  
90 patient management.

91

## 92 METHODS

93

### 94 *Search Strategy*

95 We retrieved all original studies evaluating the effect of DM on the PK of all TB drugs  
96 recommended by the WHO for the treatment of drug-sensitive (DS) and drug-resistant TB.  
97 We systematically searched major databases including conference abstracts from 1946 to  
98 6<sup>th</sup> of July 2023 using Medical Subject Headings (MeSH) terms (Supplementary Material).  
99 We also manually screened the references of included original studies. To identify  
100 unpublished studies, <http://clinicaltrials.gov> was searched. This systematic review was  
101 conducted in accordance with the PRISMA statement. The protocol was registered at  
102 PROSPERO (CRD42022323566).

103

### 104 **Study Selection**

105 Studies that reported PK of anti-TB medications among DM and non-DM participants were  
106 included. No restrictions on language and publication date were applied. General PK  
107 studies reporting a subgroup of DM participants were not eligible unless they included  
108 detailed PK parameters for DM and non-DM participants. Review articles, letters, case  
109 reports and case series with less than five participants were excluded, as were non-human  
110 studies.

111

### 112 **Data Extraction**

113 Two authors screened and retrieved articles according to the eligibility criteria and  
114 performed full text review and final article selection. The following variables were  
115 extracted: demographics of comparator group(s) and the DM group including age, weight,  
116 and sex, study design, DM diagnosis, and DM medications, dose, dosing interval,  
117 sampling points, AUC, peak drug concentration ( $C_{max}$ ), half-life ( $t_{1/2}$ ), time to reach  $C_{max}$   
118 ( $T_{max}$ ), volume of distribution (Vd) and clearance (CL) and were stratified by group. If these  
119 data were not reported, we also contacted the authors to request the data.

120

### 121 **Risk of bias in included studies**

122 In the absence of available tools to assess risk of bias in PK studies, we assessed study  
123 quality and risk of bias using the ROBINS-I tool for non-randomised studies of  
124 interventions.<sup>14</sup> Any disagreements regarding grading of quality were resolved through  
125 discussion with a third author.

126

### 127 **Analysis**

128 Narrative synthesis of the findings was conducted and reported according to the Synthesis  
129 Without Meta-analysis (SWiM) guidelines. Descriptive statistics was used to describe key

130 outcome measures. The pooled mean difference (MD) and 95% confidence interval (CI)  
131 was calculated for the main PK parameters of RIF, INH, PZA and ethambutol (ETB),  
132 through a random-effects model, when at least data from two studies were available. We  
133 compared values between TB patients with and without DM. Data expressed as medians  
134 (with interquartile range, IQR) were converted to means and standard deviations (SD).<sup>15</sup>  
135 The pooling was performed according to an available case analysis scenario. Studies  
136 reporting means without SD values, medians without enough data to derive means and  
137 those reporting geometric means were excluded, since arithmetic means cannot be  
138 computed without raw data and log-transformed data cannot be mixed with untransformed  
139 ones in a meta-analysis.<sup>16</sup> To express the amount of heterogeneity and estimate the  
140 between-study variance, when at least three studies were available for pooling a prediction  
141 interval (PI), was calculated.<sup>17</sup> All calculations were carried out using R software, version  
142 4.1.0, 'meta' package.

143

## 144 **RESULTS**

145 4173 potentially relevant articles were identified. After removing duplicates, 3464 articles  
146 were retrieved for initial screening and 49 studies were included for full text review. After  
147 reviewing the eligibility criteria, 21 articles were included that assessed the PK of anti-TB  
148 medications among TB-DM patients.<sup>11,18-37</sup> Five included papers presented the same  
149 data: in conference abstract<sup>38-42</sup> and then in published form;<sup>19,25,29,32,39</sup> we included data  
150 from the published report. One study was only published as a conference abstract and the  
151 authors were not able to share data at the time of this review.<sup>43</sup> No relevant unpublished  
152 studies were found. The study selection process is recorded in a PRISMA flow diagram  
153 (**Figure 1**).

154

### 155 ***Risk of bias assessment***

156 The risk of bias for each domain across all included studies is given in Supplementary  
157 material. While all studies have made a comparative analysis between DM and non-DM  
158 population, all had moderate to serious risk of bias in at least one domain. Overall, the  
159 existing body of literature examining PK of anti-TB medications among DM population is of  
160 medium quality.

161

### 162 ***Rifampicin (Table 1)***

163 Of the 21 studies, 16 measured RIF plasma concentrations,<sup>11,18,19,21,23,24,26-32,34-36</sup> majority  
164 of which were prospective PK studies except one retrospective study reporting results  
165 based on routinely collected data.<sup>24</sup>

166

167 Out of 16 studies, 7 reported AUC values; three with intensive sampling (> 6 samples)  
168<sup>27,28,34</sup> reporting AUC<sub>0-24</sub> mg.h/L, three reported AUC<sub>0-6</sub> mg.h/L,<sup>11,29,32</sup> and one reported  
169 AUC<sub>0-8</sub> mg.h/L.<sup>23</sup> Fifteen measured RIF peak concentrations ( $C_{max}$ ); mean absolute RIF  
170  $C_{max}$  was below the recommended range (above 8 mg/L<sup>44</sup>) in diabetic and non-diabetic  
171 groups in the majority of studies, and within the recommended range only in the 3 studies  
172 with intensive sampling.<sup>27,28,34</sup> Eight studies measured  $T_{max}$ . In a study using population  
173 PK modelling, absorption rate constant ( $k_a$ ) was significantly increased and the volume of  
174 distribution ( $V_d$ ) was significantly increased in the DM,<sup>19</sup> the authors inferring that the  
175 plasma concentrations would therefore be lower in the DM group. Another study found no  
176 difference in  $k_a$  or  $V_d$  between the TB and TB-DM groups, but reduced clearance was  
177 observed and  $V_d$  was significantly higher in the TB-DM group when  $V_d$  was normalized to  
178 total body weight.<sup>27</sup>

179

180 Raised blood glucose was inversely correlated with the rifampicin AUC/ $C_{max}$  in four  
181 studies,<sup>27,29,35,36</sup> whereas three other studies found no association.<sup>21,28,34</sup> Two studies  
182 found that body weight and plasma concentrations were inversely correlated.<sup>18,29</sup>

183

184 There were significant differences between DM and non-DM groups. Nine studies reported  
185 that DM patients had significantly higher BMI or weight<sup>11,18,21,23,26,27,29,32,35</sup> and nine studies  
186 reported the DM group to be older<sup>11,18,26-28,30,32,34,36</sup>. One study that matched based on sex  
187 and age found  $C_{max}$  and AUC to be significantly lower and  $T_{max}$  significantly longer among  
188 DM group compared to non-DM. Eight studies reported DM patients to be on diabetes  
189 treatment<sup>11,18,21,26-30,36</sup>, although no comparative analysis could be done as the majority of  
190 patients were receiving anti-diabetic medications.

191

192 Methodology differed between studies. Of the five studies finding a significantly decreased  
193  $C_{max}$  in the diabetic group, four performed only a single 2-hour sampling<sup>18,24,35,36</sup>, with one  
194 retrospective study<sup>24</sup> and one likely confounded by differences in weight (DM patients  
195 weighing more)<sup>29</sup>.

196

197 DM patients had higher weight and/or BMI and some studies demonstrated a negative  
198 association between weight and plasma concentrations. The only study that matched  
199 based on weight (within 5 kg)<sup>34</sup> found no significant difference of RIF PK between groups.  
200 RIF doses used highly differed between studies which may have influenced the results,  
201 doses used detailed in Table 1.

202

### 203 ***Isoniazid (Table 1)***

204 Nine studies assessed isoniazid (INH) PK.<sup>11,18,22-24,26,28,31,33</sup> Of these, one was based on  
205 routinely collected retrospective data,<sup>24</sup> four studies used 600 mg dosing 3 times per week  
206<sup>11,23,26,31</sup> and only 1 study sampled intensively.<sup>28</sup> Four studies assessed for NAT2 status  
207 using different methods.<sup>22,23,28,33</sup>

208

209 Out of nine studies, four assessed the mean exposure; one AUC<sub>0-24</sub> mg.h/L,<sup>28</sup> two AUC<sub>0-6</sub>  
210 mg.h/L<sup>11,33</sup> and one AUC<sub>0-8</sub> mg.h/L.<sup>23</sup> Four studies examined INH C<sub>max</sub><sup>11,18,26,28</sup> and three  
211 studies assessed T<sub>max</sub>.<sup>23,33</sup>

212

213 While one study reported concentrations to be negatively correlated with blood glucose,<sup>26</sup>  
214 in two studies INH C<sub>max</sub>/AUC was not correlated with FBG or HbA1c.<sup>22,28</sup> In one study INH  
215 concentrations were inversely correlated with weight.<sup>18</sup> There were significant differences  
216 between groups with the DM group being older and weighing more than non-DM group.

217

### 218 ***Pyrazinamide (Table 1)***

219 Pyrazinamide PK was reviewed in eight studies,<sup>11,18,23,25,26,28,31,34</sup> all of which were  
220 prospective PK studies. Patients in all studies except two were on 1500 mg PZA dosing,  
221 whilst one study used 1600 mg for patients >50 kg and 1200 mg for patients <50 kg<sup>28</sup> and  
222 other used 20-30 mg/kg.<sup>25</sup> Out of eight, four papers reported mean exposure to PZA; two  
223 reporting AUC<sub>0-24</sub> mg.h/L,<sup>28,34</sup> one AUC<sub>0-8</sub> mg.h/L<sup>23</sup> and one AUC<sub>0-6</sub> mg.h/L.<sup>11</sup> Six studies  
224 reported C<sub>max</sub> and three studies measured T<sub>max</sub>.

225

226 No correlation between FBG and AUC/C<sub>max</sub> was observed in two studies<sup>28,34</sup> whereas one  
227 study showed a negative correlation.<sup>26</sup> In a population PK modelling study,<sup>25</sup> increased  
228 apparent clearance was observed in TB-DM patients, most significantly in the group with  
229 patients >70 years and AUC<sub>0-24</sub> mg.h/L was decreased in the DM group >70 years.

230

### 231 ***Ethambutol (Table 1)***



232 Three included studies assessed the effect of DM on EMB PK.<sup>18,28,34</sup> Two reported AUC<sub>0-</sub>  
233 <sub>24</sub> mg.h/L and T<sub>max</sub><sup>28,34</sup>, all reported C<sub>max</sub>.

234

### 235 **Other agents (Table 1)**

236 Two studies assessed the effect of DM on cycloserine,<sup>37</sup> linezolid<sup>37</sup> and moxifloxacin.<sup>20</sup> A  
237 retrospective cross-sectional study reviewing the 2 h post-dose in routine practice found  
238 that 55% of the samples had below the lower limit of recommended cycloserine plasma  
239 concentrations and 17% had low linezolid concentrations.<sup>37</sup> DM patients had a lower  
240 cycloserine exposure, although this was not statistically significant, and there was no  
241 association between linezolid exposure and DM. In a recent retrospective study evaluating  
242 moxifloxacin PK, AUC<sub>0-24h</sub> was shown to be significantly lower in patients with DM  
243 compared to age, sex and RIF matched TB patients without DM.<sup>20</sup> In line, peak and  
244 trough concentrations were also reduced in DM patients. Although the drug absorption,  
245 volume of distribution and T<sub>max</sub> were comparable between TB-DM and TB patients,  
246 moxifloxacin clearance was increased in TB-DM patients.

247

### 248 **Meta-analysis**

249 A quantitative pooling was possible in seven cases, of which four involved RIF. We pooled  
250 data from four studies reporting RIF T<sub>max</sub>.<sup>27-30,34</sup> Overall, RIF T<sub>max</sub> was significantly higher  
251 in the TB-DM group: MD 0.65 (95% CI, 0.03-1.27) (Figure 2). Two studies were pooled for  
252 RIF AUC<sub>0-24</sub>,<sup>27,30</sup> four for RIF C<sub>max</sub><sup>21,23,27,30</sup> and four for RIF C<sub>2hr</sub><sup>18,26,31,35</sup>, and no  
253 statistically significant differences were detected (Figure 2-3). However, RIF C<sub>2hr</sub> was lower  
254 in TB-DM group with a MD of -1.68 (95% CI, -5.41; 2.05). In regard to other first line drugs,  
255 we observed no significant differences for INH C<sub>2hr</sub>, PZA C<sub>2hr</sub>, PZA T<sub>max</sub> and ETB T<sub>max</sub>  
256 (supplementary material).

257

### 258 **DISCUSSION**

259

260 This systematic review provides a comprehensive account of the impact of DM on the PK  
261 of anti-TB medications. While the evidence is heterogeneous, according to our analysis,  
262 RIF T<sub>max</sub> is significantly prolonged in patients with DM compared to non-DM patients;  
263 however, PI crossed the no-effect threshold, indicating that in future studies opposite  
264 results may be determined. Whereas we found no significant differences between DM and  
265 non-DM patients for RIF C<sub>max</sub>, AUC<sub>0-24</sub> or C<sub>2hr</sub>, INH C<sub>2hr</sub>, PZA C<sub>2hr</sub>, PZA T<sub>max</sub> and ETB



266  $T_{max}$ . While RIF C<sub>2hr</sub> was slightly reduced in TB-DM patients, this finding was not  
267 statistically significant.

268

269 Diabetes predominantly effects gastric motility via neuropathy.<sup>12</sup> This would be postulated  
270 to prolong  $T_{max}$  rather than reduce the overall AUC. Our findings of prolonged RIF  $T_{max}$   
271 may be a reflection of the impact of DM on gastric motility and delay in drug absorption.  
272 However, the efficacy of most of the anti-TB medications is driven by AUC, which is  
273 difficult to determine with 1 or 2 sampling timepoints. Therefore, interpretation of studies  
274 with limited sampling points should be with caution. Studies with more than one sampling  
275 point, ideally with intensive sampling comparing DM vs non-DM population, or limited  
276 sampling strategy using population PK modelling will guide our management strategy in  
277 this population.

278

279 There is some evidence that PK among DM patients, may have clinical relevance in terms  
280 of MIC and culture conversion. In a retrospective study, where all DM patients underwent  
281 TDM and dose adjustment accordingly, time to culture conversion improved significantly  
282 (average 19 days earlier) among DM patients.<sup>45</sup> Recently, studies with higher doses of  
283 RIF has demonstrated bacteriologically sustained cure in a general TB population.<sup>46</sup>  
284 Perhaps these results and the higher RIF strategy have more relevance for the TB-DM  
285 population in which we observe more heterogenous plasma concentrations and that  
286 reducing the bacterial burden quicker may result in reduced relapse rates.

287

288 We observed high variability in findings and significant heterogeneity among studies.  
289 Firstly, there were differences in terms of demographics; age, sex and body weight, DM  
290 diagnosis and anti-DM medications. Increased body surface area distribution, delayed  
291 drug absorption due to DM related gastroparesis and changes in expression of enzymes  
292 involved in metabolism<sup>47</sup> are major factors that may contribute to altered PK.<sup>12,48</sup> In most  
293 studies, DM patients weighted more than non-DM controls. However, matching weight is  
294 unlikely to eliminate potential biases as DM participants continued to receive capped  
295 dosing despite weight differences. Screening DM at the time of TB diagnosis may result  
296 in some with transient hyperglycaemia being identified as DM. While most of the patients  
297 were on anti-diabetic medications, the degree of diabetic control was not provided, limiting  
298 our understanding.

299

300 Secondly, PK sampling methodology and drug doses used varied widely across studies.  
301 Those with a single 2 hr sampling point assume  $T_{max}$  to occur at 2 hrs ( $C_{max}$ ). Therefore,  
302 studies without intensive sampling may not accurately capture the  $C_{max}$ . However, it is  
303 important to note  $T_{max}$  is highly variable for RIF in general. Particularly affecting the  
304 isoniazid studies, dosing differed markedly, with 4 out of 9 using 600 mg 3 times/week,  
305 which is no longer recommended. Only four out of 9 studies made any assessment of  
306 NAT2 acetylator status which is a key variable in isoniazid PK likely to confound results.<sup>49</sup>

307

308 We identified another systematic review assessing the impact of DM on the PK of  
309 rifampicin among TB patients<sup>50</sup>. The review included studies published up until September  
310 2020 and identified seven studies from which pooled estimates were calculated. The same  
311 authors updated their systematic review including studies with  $C_{max}$  at 2hr,<sup>51</sup> and identified  
312 17 studies reporting RIF plasma concentrations.

313

314 Our study has limitations. Firstly, we identified a limited number of PK studies despite a  
315 comprehensive literature search. Secondly, due to studies reporting geometric means we  
316 were unable to pool data from those reporting AUC 0-24. Finally, we did not include  
317 general PK studies reporting on TB-DM patients as a subgroup.

318

319 Given the association observed between dose adjustment and clinical improvement, dose  
320 adjustment based on TDM may be beneficial in this patient population. We recognise that  
321 in most global settings TDM is not easily available. Until more simplified and cost-effective  
322 tests are easily available,<sup>52</sup> the alternative would be to empirically increase drug doses in  
323 all individuals with DM. While TB drug exposures in diabetes is mixed, given RIF has a  
324 wide therapeutic window<sup>53</sup> and successful treatment outcome depends on sufficient drug  
325 exposure, we recommend considering a higher dose limit for patients with DM; instead of  
326 capped dosing, using 10mg/kg to be able to correct for larger bodyweight of patients with  
327 DM. This is also a group that should be prioritised in ongoing studies addressing  
328 empirically increasing doses of TB medications. In order to achieve definitive answers for  
329 PK in DM population, we recommend important considerations as in **Table 2**.

330

### 331 **Acknowledgements**

332 This work was supported by the Chief Scientist Office (CAF/20/03) and British Infection  
333 Association (Grant/2022/SPG/MC) received by MC.

334

335 **Author contributions**

336 MC conceptualized the scope of the review, led the systematic review, literature search,  
337 data collection and wrote the first and subsequent drafts of the manuscript. AS involved in  
338 creating the table from selected papers. AEM performed the meta-analysis on selected  
339 papers. All authors contributed to the final version of the manuscript and approved it for  
340 publication.

341

342 **Declaration of Interests**

343 No conflict of interests reported.

344

345 **Figures and tables:**

346 Figure 1: Flowchart describing study selection

347 Figure 2: Meta-analysis of Rifampicin (RIF AUC<sub>0-24</sub> and RIF T<sub>max</sub>)

348 Figure 3: Meta-analysis of Rifampicin (RIF C<sub>max</sub> and C<sub>2hr</sub>)

349 Table 1: Summary of included studies

350 Table 2: Recommendations for future research

351 **References:**

- 352 1. WHO. World Health Organization, Global tuberculosis report 2022  
353 . 2022. <https://www.who.int/publications/i/item/9789240061729>.
- 354 2. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of  
355 diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018; **138**:  
356 271-81.
- 357 3. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active  
358 tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with  
359 tuberculosis. *Lancet Glob Health* 2019; **7**(4): e448-e60.
- 360 4. Koesoemadinata RC, McAllister SM, Soetedjo NNM, et al. Latent TB infection and  
361 pulmonary TB disease among patients with diabetes mellitus in Bandung, Indonesia.  
362 *Trans R Soc Trop Med Hyg* 2017; **111**(2): 81-9.
- 363 5. Foe-Essomba JR, Kenmoe S, Tchatchouang S, et al. Diabetes mellitus and  
364 tuberculosis, a systematic review and meta-analysis with sensitivity analysis for studies  
365 comparable for confounders. *PLoS One* 2021; **16**(12): e0261246.
- 366 6. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis  
367 treatment outcomes: a systematic review. *BMC Med* 2011; **9**: 81.
- 368 7. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes  
369 on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. *Int*  
370 *J Tuberc Lung Dis* 2019; **23**(7): 783-96.
- 371 8. Dong Z, Shi J, Dorhoi A, et al. Hemostasis and Lipoprotein Indices Signify  
372 Exacerbated Lung Injury in TB With Diabetes Comorbidity. *Chest* 2018; **153**(5): 1187-200.
- 373 9. Salindri AD, Kipiani M, Kempker RR, et al. Diabetes Reduces the Rate of Sputum  
374 Culture Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis.  
375 *Open Forum Infect Dis* 2016; **3**(3): ofw126.
- 376 10. Zheng X, Bao Z, Forsman LD, et al. Drug Exposure and Minimum Inhibitory  
377 Concentration Predict Pulmonary Tuberculosis Treatment Response. *Clin Infect Dis* 2021;  
378 **73**(9): e3520-e8.
- 379 11. Alfarisi O, Mave V, Gaikwad S, et al. Effect of Diabetes Mellitus on the  
380 Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment. *Antimicrob Agents*  
381 *Chemother* 2018; **62**(11): 11.
- 382 12. Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on  
383 pharmacokinetic and pharmacodynamic properties of drugs. *Clin Pharmacokinet* 2012;  
384 **51**(8): 481-99.
- 385 13. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical  
386 and molecular perspective. *Antimicrob Agents Chemother* 2002; **46**(2): 267-74.
- 387 14. Gafar F, Wasmann RE, McIlhleron HM, et al. Global estimates and determinants of  
388 antituberculosis drug pharmacokinetics in children and adolescents: a systematic review  
389 and individual patient data meta-analysis. *Eur Respir J* 2023; **61**(3).
- 390 15. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard  
391 deviation from the sample size, median, range and/or interquartile range. *BMC Med Res*  
392 *Methodol* 2014; **14**: 135.
- 393 16. Deeks JJ HJ, Altman DG Chapter 10: Analysing data and undertaking meta-  
394 analyses. Cochrane Handbook for Systematic Reviews of Interventions version 6.4  
395 (updated August 2023). Cochrane, 2023. .
- 396 17. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses.  
397 *BMJ* 2011; **342**: d549.
- 398 18. Babalik A, Ulus IH, Bakirci N, et al. Plasma concentrations of isoniazid and rifampin  
399 are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. *Antimicrob*  
400 *Agents Chemother* 2013; **57**(11): 5740-2.

- 401 19. Chang MJ, Chae JW, Yun HY, et al. Effects of type 2 diabetes mellitus on the  
402 population pharmacokinetics of rifampin in tuberculosis patients. *Tuberculosis (Edinb)*  
403 2015; **95**(1): 54-9.
- 404 20. Dekkers BGJ, Bolhuis MS, Beek LT, et al. Reduced moxifloxacin exposure in  
405 patients with tuberculosis and diabetes. *European Respiratory Journal* 2019; **54**(3) (no  
406 pagination).
- 407 21. Fonseca AAD, Pinto ACG, Paixao TPD, Alberio CAA, Vieira JLF. Can diabetes  
408 mellitus modify the plasma concentrations of rifampicin in patients under treatment for  
409 tuberculosis? *Brazilian Journal of Infectious Diseases* 2020; **24**(4): 352-5.
- 410 22. Galvao FES, Fonseca AAD, Pinto ACG, da Paixao TP, Alberio CAA, Vieira JLF. No  
411 significant influence of diabetic mellitus on isoniazid plasma levels in patients under  
412 treatment for tuberculosis. *Infectious Diseases* 2020; **52**(8): 577-80.
- 413 23. Hemanth Kumar AK, Kannan T, Chandrasekaran V, et al. Pharmacokinetics of  
414 thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.  
415 *Int J Tuberc Lung Dis* 2016; **20**(9): 1236-41.
- 416 24. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow  
417 response to tuberculosis treatment in a state control program, Virginia, USA. *Emerg Infect*  
418 *Dis* 2010; **16**(10): 1546-53.
- 419 25. Kim R, Jayanti RP, Kim HK, et al. Development of a population pharmacokinetic  
420 model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes  
421 mellitus on clearance. *Front Pharmacol* 2023; **14** (no pagination): 1116226.
- 422 26. Kumar AK, Chandrasekaran V, Kannan T, et al. Anti-tuberculosis drug  
423 concentrations in tuberculosis patients with and without diabetes mellitus. *Eur J Clin*  
424 *Pharmacol* 2017; **73**(1): 65-70.
- 425 27. Medellin-Garibay SE, Cortez-Espinosa N, Milan-Segovia RC, et al. Clinical  
426 Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus:  
427 Association with Biochemical and Immunological Parameters. *Antimicrob Agents*  
428 *Chemother* 2015; **59**(12): 7707-14.
- 429 28. Mtabho CM, Semvua HH, van den Boogaard J, et al. Effect of diabetes mellitus on  
430 TB drug concentrations in Tanzanian patients. *J Antimicrob Chemother* 2019; **74**(12):  
431 3537-45.
- 432 29. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly  
433 reduced in patients with tuberculosis and type 2 diabetes. *Clin Infect Dis* 2006; **43**(7): 848-  
434 54.
- 435 30. Perea-Jacobo R, Muniz-Salazar R, Laniado-Laborin R, Cabello-Pasini A, Zenteno-  
436 Cuevas R, Ochoa-Teran A. Rifampin pharmacokinetics in tuberculosis-diabetes mellitus  
437 patients: a pilot study from Baja California, Mexico. *Int J Tuberc Lung Dis* 2019; **23**(9):  
438 1012-6.
- 439 31. Ramachandran G, Chandrasekaran P, Gaikwad S, et al. Subtherapeutic rifampicin  
440 concentration is associated with unfavorable tuberculosis treatment outcomes. *Clin Infect*  
441 *Dis* 2020; **70**(7): 1463-70.
- 442 32. Requena-Mendez A, Davies G, Ardrey A, et al. Pharmacokinetics of rifampin in  
443 Peruvian tuberculosis patients with and without comorbid diabetes or HIV. *Antimicrob*  
444 *Agents Chemother* 2012; **56**(5): 2357-63.
- 445 33. Requena-Mendez A, Davies G, Waterhouse D, et al. Effects of dosage,  
446 comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.  
447 *Antimicrob Agents Chemother* 2014; **58**(12): 7164-70.
- 448 34. Ruslami R, Nijland HM, Adhiarta IG, et al. Pharmacokinetics of antituberculosis  
449 drugs in pulmonary tuberculosis patients with type 2 diabetes. *Antimicrob Agents*  
450 *Chemother* 2010; **54**(3): 1068-74.
- 451 35. Samuel Gideon George P, Saranya P. Effect of patient-specific variables on  
452 rifampicin peak serum concentration. *Drug Invention Today* 2018; **10**(3): 290-6.




- 453 36. Saranya P, Parthasarathy V, Hariprasad B, Shobha Rani H. Effect of diabetes  
454 mellitus on rifampicin peak serum concentration. *International Journal of Pharmacy and*  
455 *Pharmaceutical Sciences* 2016; **8(10)**: 149-52.
- 456 37. Zhu H, Guo SC, Liu ZQ, et al. Therapeutic drug monitoring of cycloserine and  
457 linezolid during anti-tuberculosis treatment in Beijing, China. *Int J Tuberc Lung Dis* 2018;  
458 **22(8)**: 931-6.
- 459 38. Chang MJ, Shin W, Song J, et al. The pharmacokinetics of four standard anti-  
460 tuberculosis drugs in tuberculosis patients with diabetes mellitus. *Respirology* 2009; **3**):  
461 A231.
- 462 39. Mtabho C, Semvua H, Kibiki G, Tostmann A, Aarnoutse R. The effect of diabetes  
463 mellitus on the pharmacokinetics of tuberculosis drugs in Tanzanian patients. *Tropical*  
464 *Medicine and International Health* 2015; **1**): 23.
- 465 40. Nijland H, Ruslami R, Stalenhoef J, et al. Exposure to rifampicin is reduced by 53%  
466 in tuberculosis patients with Diabetes Mellitus. *Br J Clin Pharmacol* 2006; **62(6)**: 730-.
- 467 41. Mendez AR, Moore DAJ, Davies G. Improving management of TB in the tropics  
468 Rifampicin pharmacokinetics in peruvian tuberculosis patients with and without co-morbid  
469 diabetes or HIV. *Tropical Medicine and International Health* 2011; **1**): 62.
- 470 42. Kim R, Jayanti R, Jang T, et al. Development of Population Pharm Aco Kin Etics  
471 Model of Pyrazinamide and Optimal Dose Recommendation for Elderly with Diabetes  
472 Mellitus in Korean Tuberculosis Patients. *Clinical Pharmacology and Therapeutics* 2023;  
473 **113(Supplement 1)(S1)**: S94.
- 474 43. Christopher DJ, Jedidiah D, Isaac B, Mathew B, Winston B. Anti-tubercular drug  
475 concentrations in pulmonary tuberculosis patients-diabetic vs non-diabetic groups.  
476 *European Respiratory Journal Conference: 29th International Congress of the European*  
477 *Respiratory Society, ERS Madrid Spain 2019*; **54(Supplement 63)**.
- 478 44. Peloquin CA, Velasquez GE, Lecca L, et al. Pharmacokinetic Evidence from the  
479 HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. *Antimicrob Agents*  
480 *Chemother* 2017; **61(8)**.
- 481 45. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for  
482 diabetes related tuberculosis associate with hastened sputum microbiological clearance in  
483 Virginia, USA. *BMC Infect Dis* 2017; **17(1)**: 125.
- 484 46. Paton NI, Cousins C, Suresh C, et al. Treatment Strategy for Rifampin-Susceptible  
485 Tuberculosis. *N Engl J Med* 2023; **388(10)**: 873-87.
- 486 47. Kuppusamy UR, Indran M, Rokiah P. Glycaemic control in relation to xanthine  
487 oxidase and antioxidant indices in Malaysian Type 2 diabetes patients. *Diabet Med* 2005;  
488 **22(10)**: 1343-6.
- 489 48. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on  
490 pharmacokinetics and pharmacodynamics in humans. *Clin Pharmacokinet* 1991; **20(6)**:  
491 477-90.
- 492 49. Hong BL, D'Cunha R, Li P, et al. A Systematic Review and Meta-analysis of  
493 Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis. *Clin*  
494 *Ther* 2020; **42(11)**: e220-e41.
- 495 50. Metwally AS, El-Sheikh SMA, Galal AAA. The impact of diabetes mellitus on the  
496 pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and  
497 meta-analysis study. *Diabetes Metab Syndr* 2022; **16(2)**: 102410.
- 498 51. El-Sheikh SMA, Metwally AS, Galal AAA. Impact of diabetes mellitus on rifampicin's  
499 plasma concentration and bioavailability in patients with tuberculosis: A systematic review  
500 and meta-analysis study. *Therapie* 2023; **78(3)**: 313-24.
- 501 52. Xie YL, Modi N, Handler D, et al. Simplified urine-based method to detect rifampin  
502 underexposure in adults with tuberculosis: a prospective diagnostic accuracy study.  
503 *Antimicrob Agents Chemother* 2023; **67(11)**: e0093223.

504 53. Akkerman OW, Dijkwel RDC, Kerstjens HAM, et al. Isoniazid and rifampicin  
505 exposure during treatment in drug-susceptible TB. *Int J Tuberc Lung Dis* 2023; **27**(10):  
506 772-7.  
507  
508  
509



Figure 1. Flowchart describing study selection



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).